Clinical efficacy of human interferon vaginal effervescent tablets combined with pidotimod in treatment of cervical HPV infection
GAO Zhenzhen1, LI Weiping1, ZHANG Xiaoli1, CHEN Di2, TONG Jun1
1. Department of Gynecology, the Third Medical Center of PLA General Hospital, Beijing 100039, China; 2. Department of Obsetrics, the Third Medical Center of PLA General Hospital, Beijing 100039, China
Abstract：Objective To investigate the clinical efficacy of human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid in the treatment of persistent cervical high-risk type human papilloma virus (HPV).Methods A total of 211 cases with persistent cervical high-risk type HPV infection diagnosed in the Third Medical Center of PLA General Hospital were collected from January 2019 to December 2020, and they were randomly divided into two groups according to treatment options. The experimental group of 109 cases were treated with human interferon a2b vaginal effervescent tablets combined with pidotimod oral liquid, while the control group of 102 cases were treated with human interferon a2b vaginal effervescent tablets as single-agent therapy. The outcomes of cervical high-risk HPV at 6 months and 12 months after treatment were compared between the two groups.Results The effective rate (all negative conversion rate) of HPV was 51.38% (56/109) in the experimental group and 23.53% (24/102) in the control group after 6 months’ treatment, and there was a significant difference between the two groups (P<0.05).The effective rate of HPV was 73.39% (80/109) in the experimental group and 42.16% (43/102) in the control group after 12 months’ treatment, and there was a significant difference between the two groups (P<0.05). Further analysis of HPV typing remaining positive in the experimental group and the control group was conducted, and the effective rate of the top three types (HPV16/18, HPV52 and HPV58) after treatment in the experimental group was better than that in the control group.Conclusion Human interferon a2b vaginal effervescent tablets combined with Pidotimod oral liquid can effectively improve the negative conversion rate of cervical high-risk type HPV, and more effective for removal of cervical HPV16/18 infection, which provides a reference for clinical treatment of HPV persistent infection.
Harper D M,Franco E L,Wheeler C,et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a fandomised controlled trial[J].Lancet,2004,364(9447):1757-1765.
Hou S,Yuan L,Jin P,et al.A clinical study of the effects of lead poisoning on the intelligence and neurobehavioral abilities of children[J]. Theor Biol Med Model,2013,10:13.
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention[OL].[2021-07-07]https://www.who.int/publications/i/ite m/9789240030824.
Zhang L,Bi Q, Deng H,et al. Human papilloma virus infection among women with cervical lesions and cervical cancer in eastern China:genotype-specific prevalence and attribution[J]. BMC Infect Dis, 2017,17(1):107.
2022, Vol. 33 
